Title:Redox Modulation of Meniere Disease by Coriolus versicolor Treatment, a
Nutritional Mushroom Approach with Neuroprotective Potential
Volume: 22
Issue: 12
Author(s): Rosanna Di Paola, Rosalba Siracusa, Roberta Fusco, Marialaura Ontario, Gaetano Cammilleri, Licia Pantano, Maria Scuto, Mario Tomasello, Sestina Spanò, Angela Trovato Salinaro, Ali S. Abdelhameed, Vincenzo Ferrantelli, Antonio Arcidiacono, Tilman Fritsch, Gabriella Lupo*, Anna Signorile*, Luigi Maiolino, Salvatore Cuzzocrea and Vittorio Calabrese
Affiliation:
- Department of Biomedical and
Biotechnological Sciences; Department of Medical, Surgical Advanced Technologies "G.F. Ingrassia", University of
Catania, Italy
- Department of Translational Biomedicine and Neuroscience, University of Bari, Aldo Moro,
70124, Bari, Italy
Keywords:
Redoxomics, meniere’s disease, glutathione, neurodegenerative diseases, Coriolus versicolor, vitagene pathway, inflammation.
Abstract:
Background: Meniere's disease (MD) is a cochlear neurodegenerative disease. Hearing loss
appears to be triggered by oxidative stress in the ganglion neurons of the inner ear.
Objective: Here, we confirm the variation of markers of oxidative stress and inflammation in patients
with Meniere and hypothesize that chronic treatment with Coriolus mushroom helps in the response to
oxidative stress and acts on α-synuclein and on NF-kB-mediated inflammatory processes
Methods: Markers of oxidative stress and inflammation were evaluated in MD patients with or without
Coriolus treatment for 3 or 6 months.
Results: MD patients had a small increase in Nrf2, HO-1, γ-GC, Hsp70, Trx and sirtuin-1, which were
further increased by Coriolus treatment, especially after 6 months. Increased markers of oxidative
damage, such as protein carbonyls, HNE, and ultraweak chemiluminescence, associated with a decrease
in plasma GSH/GSSG ratio, were also observed in lymphocytes from MD patients. These parameters
were restored to values similar to the baseline in patients treated with Coriolus for both 3 and
6 months. Furthermore, treated MD subjects showed decreased expression of α-synuclein, GFAP and
Iba-1 proteins and modulation of the NF-kB pathway, which were impaired in MD patients. These
changes were greatest in subjects taking supplements for 6 months.
Conclusion: Our study suggests MD as a model of cochlear neurodegenerative disease for the identification
of potent inducers of the Nrf2-vitagene pathway, able to reduce the deleterious consequences
associated with neurodegenerative damage, probably by indirectly acting on a-synuclein expression
and on inflammatory processes NF-kB-mediated.
